NMPA Accepted New Drug Application for DBPR108
NHRI announced that the National Medical Products …
分類: News & Events
DBPR22998: A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRPα Axis for Cancer Immunotherapy
CD47-SIRPα “Do-not-eat- me” signaling axis is myel…
Novel AXL and MERTK Dual Kinase Inhibitor as Anti-Tumor and Immunomodulatory Agent
During the past two decades, the paradigm for canc…
NHRI Enters Technology Transfer Agreement of DBPR186 with Taivex Therapeutics Corp.
National Health Research Institutes (NHRI) and Tai…
NHRI Enters Technology Transfer Agreement of DBPR114 with LaunXP Biomedical Co., Ltd.
National Health Research Institutes (NHRI) and Lau…
NHRI Enters Technology Transfer Agreement of DBPR215 with Jiayi Biomedical Co., Ltd.
National Health Research Institutes (NHRI) and Jia…
National Health Research Institutes Announces the Initiation of Phase I Clinical Trial of DBPR115, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan
With budget supporting from Ministry of Economic A…
NHRI Enters Technology Transfer Agreement of DBPR211 with Applied Biopharma LLC, wholly owned by Agentix Corp. (AGTX) in the US
National Health Research Institutes (NHRI) and App…
Congratulations! Dr. Ta-Yuan Chang is elected as a member of the U.S. National Academy of Sciences.
We are honored to announce a good news that Profes…
A Safer Opioid Painkiller with Low Side-Effects─NHRI has discovered a series of opioid receptor/nociception receptor dual agonists with fast and potent antinociception, fewer side-effects than morphine
The Ministry of Science and Technology has present…
DBPR22998: A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRPα Axis for Cancer Immunotherapy
CD47-SIRPα “Do-not-eat- me” signaling axis is myel…
Novel AXL and MERTK Dual Kinase Inhibitor as Anti-Tumor and Immunomodulatory Agent
During the past two decades, the paradigm for canc…
NHRI Enters Technology Transfer Agreement of DBPR186 with Taivex Therapeutics Corp.
National Health Research Institutes (NHRI) and Tai…
NHRI Enters Technology Transfer Agreement of DBPR114 with LaunXP Biomedical Co., Ltd.
National Health Research Institutes (NHRI) and Lau…
NHRI Enters Technology Transfer Agreement of DBPR215 with Jiayi Biomedical Co., Ltd.
National Health Research Institutes (NHRI) and Jia…
National Health Research Institutes Announces the Initiation of Phase I Clinical Trial of DBPR115, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan
With budget supporting from Ministry of Economic A…
NHRI Enters Technology Transfer Agreement of DBPR211 with Applied Biopharma LLC, wholly owned by Agentix Corp. (AGTX) in the US
National Health Research Institutes (NHRI) and App…
Congratulations! Dr. Ta-Yuan Chang is elected as a member of the U.S. National Academy of Sciences.
We are honored to announce a good news that Profes…
A Safer Opioid Painkiller with Low Side-Effects─NHRI has discovered a series of opioid receptor/nociception receptor dual agonists with fast and potent antinociception, fewer side-effects than morphine
The Ministry of Science and Technology has present…